Discover what three prominent CEOs predict for the biopharma industry in 2024 and reflect on the groundbreaking advancements of 2023.
The year 2023 marked significant advancements in biopharma, with notable milestones such as the approval of the Alzheimer’s disease drug Leqembi and the first CRISPR-edited therapy.
As we reflect on these pivotal moments and anticipate what 2024 holds, GEN engaged CEOs from three prominent companies—Zevra Therapeutics, Axogen, and Ryght—to share insights on the broader industry landscape and their respective company strategies.
Neil McFarlane of Zevra highlights the company's recent acquisition and its progress towards treating Niemann-Pick disease type C. Karen Zaderej from Axogen discusses the company's growth trajectory and the launch of innovative nerve products.
Simon Arkell of Ryght delves into the company's generative AI platform to enhance biopharma decision-making.
Read the full article here on genengnews.com
Ryght AI is building what it calls the world’s first “agentic AI platform” for clinical trials. The company’s system automates site selection,...
Synthetica Bio taps into generative AI and strategic partnerships to revolutionize drug discovery. This innovation aims to empower biopharma...
Press release announcing the company's rebranding from Synthetica Bio to Ryght with a focus on delivering trusted insights to biopharma.